The long-term prognostic value of multiple biomarkers following a myocardial infarction

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 60-66

  Brügger Andersen, Trygve ^a,b   Aarsetøy, Hildegunn ^a,b   Grundt, Heidi ^a,b   Staines, Harry ^c   Nilsen, Dennis W T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c Sigma Statistical Services   (United Kingdom)

Author keywords

Biomarkers; Myocardial infarction; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; FIBRIN MONOMER; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEROXIDASE; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 54149114903     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.01.012     Document Type: Article

References (38)

1. Yeghiazarians Y., Braunstein J.B., Askari A., and Stone P.H. Unstable angina pectoris. N Engl J Med 342 (2000) 101-114
2. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
3. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
4. Bodi V., Sanchis J., Llacer A., Facila L., Nunez J., Pellicer M., et al. Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. Am Heart J 149 (2005) 268-274
5. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.M., Murphy S.A., Rifai N., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
6. Nilsen D.W., Albrektsen G., Landmark K., Moen S., Aarsland T., and Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 74 (2001) 50-56
7. World Health Organisation. Myocardial Infarction Community Registers (1976), World Health Organisation, Copenhagen
8. Wu A.H., Apple F.S., Gibler W.B., Jesse R.L., Warshaw M.M., and Valdes Jr. R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 45 (1999) 1104-1121
9. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
10. Grundt H., Nilsen D.W., Hetland O., Valente E., and Fagertun H.E. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 147 (2004) 260-266
11. Hetland O., Knudsen A., Dickstein K., and Nilsen D.W. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagul Fibrinolysis 13 (2002) 301-308
12. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
13. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
14. Omland T., Aakvaag A., Bonarjee V.V., Caidahl K., Lie R.T., Nilsen D.W., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93 (1996) 1963-1969
15. Bibbins-Domingo K., Gupta R., Na B., Wu A.H., Schiller N.B., and Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297 (2007) 169-176
16. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
17. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
18. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
19. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
20. de Winter R.J., Stroobants A., Koch K.T., Bax M., Schotborgh C.E., Mulder K.J., et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 94 (2004) 1481-1485
21. Schnabel R., Rupprecht H.J., Lackner K.J., Lubos E., Bickel C., Meyer J., et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 26 (2005) 241-249
22. Laursen L.S., Overgaard M.T., Nielsen C.G., Boldt H.B., Hopmann K.H., Conover C.A., et al. Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis. Biochem J 367 (2002) 31-40
23. Bayes-Genis A., Schwartz R.S., Lewis D.A., Overgaard M.T., Christiansen M., Oxvig C., et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 335-341
24. Bayes-Genis A., Conover C.A., Overgaard M.T., Bailey K.R., Christiansen M., Holmes Jr. D.R., et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 345 (2001) 1022-1029
25. Zeng B., Prasan A., Fung K.C., Solanki V., Bruce D., Freedman S.B., et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 35 (2005) 331-335
26. Torzewski M., Suriyaphol P., Paprotka K., Spath L., Ochsenhirt V., Schmitt A., et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 24 (2004) 2130-2136
27. Bayes-Genis A., Conover C.A., Overgaard M.T., Bailey K.R., Christiansen M., Holmes Jr. D.R., et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 345 (2001) 1022-1029
28. Klebanoff S.J. Myeloperoxidase. Proc Assoc Am Physicians 111 (1999) 383-389
29. Baldus S., Heeschen C., Meinertz T., Zeiher A.M., Eiserich J.P., Munzel T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
30. Brennan M.L., Penn M.S., Van L.F., Nambi V., Shishehbor M.H., Aviles R.J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
31. Fu X., Kassim S.Y., Parks W.C., and Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276 (2001) 41279-41287
32. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
33. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
34. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
35. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
36. Kruskal J.B., Commerford P.J., Franks J.J., and Kirsch R.E. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 317 (1987) 1361-1365
37. Heeschen C., Hamm C.W., Mitrovic V., Lantelme N.H., and White H.D. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110 (2004) 3206-3212
38. Weber M., Kleine C., Keil E., Rau M., Berkowitsch A., Elsaesser A., et al. Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95 (2006) 270-280